![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Switching from Stable Lopinavir/Ritonavir (LPV/r)-Based to Raltegravir (RAL)-Based Combination Antiretroviral Therapy (ART) Resulted In a Superior Lipid Profile at Week 12 but Did Not Demonstrate Non-Inferior Virologic Efficacy at Week 24 (SWITCHMRK)
|
|
|
Reported by Jules Levin
CROI 2009, Feb 7-12
Montreal Canada
Joseph Eron*1, Jaime Andrade2, Roberto Zajdenverg3, Cassy Workman4, David A. Cooper5, Benjamin Young6, Xia Xu7,
Bach-Yen Nguyen7, Randi Leavitt7, and Peter Sklar7
1University of North Carolina, Chapel Hill, NC, USA; 2Antinguo Hospital Civil de Guadalajara, Guadalajara, Mexico; 3Hospital Escola Sao Francisco de Assis, Rio de Janeiro, Brazil; 4AIDS Research Initiative, Darlinghurst, Australia; 5University of New South Wales, Sydney, Australia; 6Denver Infectious Disease Consultants, Denver, CO, USA; and 7Merck Research Laboratories, West Point, PA, USA
![swith-1.gif](../images/021109/swith-1.gif)
![stdy-2.gif](../images/021109/stdy-2.gif)
![Prot-3.gif](../images/021109/Prot-3.gif)
![RAl-4.gif](../images/021109/RAl-4.gif)
![ART-5.gif](../images/021109/ART-5.gif)
![more-6.gif](../images/021109/more-6.gif)
![lipids-7.gif](../images/021109/lipids-7.gif)
![NC-8.gif](../images/021109/NC-8.gif)
![Failures-9.gif](../images/021109/Failures-9.gif)
![CON-10.gif](../images/021109/CON-10.gif)
![OF-11.gif](../images/021109/OF-11.gif)
![Grade-12.gif](../images/021109/Grade-12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|